PALOMA-3 update, including OS data for HR positive HER2 negative breast cancer

Bookmark and Share
Published: 20 Oct 2018
Views: 1082
Rating:
Save
Prof Massimo Cristofanilli - Feinberg School of Medicine, Chicago, USA

Prof Massimo Cristofanilli speaks with ecancer at ESMO 2018 in Munich about the analysis of data from the PALOMA-3 study of palbociclib with fulvestrant to treat HR /HER2- breast cancer, following the previous publication of PFS data.

He outlines the importance of prior sensitisation with endocrine therapy in this population, and recommends the combination as a new standard of care.

For more on this trial, watch his presentation of data at a conference session here.

ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.